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Abstract
Background: The nuclear and steroid hormone receptors
function as ligand-dependent transcriptional regulators in eukary-
otes. Hormone receptors have been engineered to selectively
respond to synthetic ligands and used as remote regulators of gene
expression for the study of gene function and as potential
regulators of gene therapies.
Results: In this work, a new ligand^receptor engineering
strategy called ‘polar-group exchange’ is used to create a mutant
form of the estrogen receptor, ER(Glu353CAla), which lacks a
carboxyl group critical for high-affinity binding of estradiol, but is
able to transactivate in response to nanomolar concentrations of a
carboxylate-functionalized estrogen analog, ES8. ES8 activates
ER(Glu353CAla) at concentrations that do not appreciably
activate the ‘wild-type’ receptor ER(wt). Two similar carboxylate-
functionalized ligands, ES6 and ES7, do not induce transactiva-
tion function. Similar selectivities are observed in ligand-binding
assays in vitro, which follow the trends predicted by molecular
modeling.
Conclusions: Polar-group exchange is an effective strategy for
rationally engineering ligand^receptor pairs. The ER(E353A)/ES8
ligand^receptor pair should constitute a unique and functionally
orthogonal ligand-dependent transcriptional regulator. ß 2001
Elsevier Science Ltd. All rights reserved.
Keywords: Gene expression regulation; Estrogen receptor; Polar-group
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1. Introduction
As we enter the post-genomic era, the need to identify
the functions of the tens of thousands of newly discovered
genes presents a new and daunting challenge. Systems for
conditionally controlling gene expression provide a power-
ful new tool for discovering the roles of speci¢c genes in
development, homeostasis and programmed cell death and
as potential regulators of gene therapies [1^3]. Ligand-de-
pendent transcriptional regulators, such as the tetracy-
cline-inducible expression system [4^6], the ecdysone re-
ceptor [7,8], RNA aptamers [9], and chemical inducers of
dimerization [10^12], allow for the precise temporal con-
trol of gene expression in eukaryotic systems. For the
study of many genes, which may be expressed only tran-
siently or which may be toxic, inducible expression sys-
tems provide a level of temporal control that is not gen-
erally achievable using transgenic ‘knock-outs’.
1.1. The steroid/nuclear hormone receptors act as
ligand-dependent transcriptional regulators
The steroid/nuclear hormone receptors function as nat-
ural ligand-dependent transcriptional regulators of speci¢c
genes involved in development and homeostasis [13^15].
The actions of steroid/nuclear hormone receptors are
mediated primarily by two functional domains, a ligand-
binding domain (LBD) which mediates ligand-dependent
transactivation function [16^18], and a DNA-binding do-
main (DBD) which targets speci¢c hormone response ele-
ments (HREs) [19,20]. Several examples of transcription-
ally active chimeric receptors, created by fusing the LBDs
of steroid/nuclear hormone receptors to DBDs of other
proteins, suggest that in principle, the ligand-dependent
transactivation functions of hormone receptors can be tar-
geted to virtually any gene [13,21^27]. In the absence of
ligand, steroid hormones are generally associated with
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heat-shock proteins (HSPs) [28] but dissociate from HSPs
upon ligand binding, dimerize and bind to speci¢c HREs.
The liganded form of the receptor associates with tran-
scriptional co-activators, which interact directly with the
basal transcription machinery (Fig. 1).
1.2. Ligand^receptor engineering is providing unique tools
for chemical biology
The ability to create ligands that can selectively bind
and activate engineered proteins represents one of the
most powerful tools of chemical biology. (For a recent
review see [29].) Most reported examples of ligand^recep-
tor engineering are based on the ‘bump and hole’ strategy
¢rst described by Schreiber for re-engineering the complex
formed by cyclophilin A and cyclosporin A [30]. Many
reported examples of engineered ligand^receptor pairs in-
volve modi¢cation of non-polar ligand^receptor interac-
tions and often these modi¢ed receptors still exhibit sig-
ni¢cant a⁄nity for their natural ligands [29]. In this work
a new strategy, we call ‘polar-group exchange’, is used to
create a high-a⁄nity ligand for a modi¢ed estrogen recep-
tor (ER) by changing the covalent connectivity of polar
groups involved in an intra-molecular protein salt-bridge.
The new ligand^receptor pair can function as a unique
transcriptional regulator and is functionally orthogonal
to both the natural ligand and receptor.
2. Results and discussion
2.1. New transcriptional regulators from engineered
hormone receptors
Hormone receptors have been modi¢ed by site-speci¢c
or random mutagenesis to selectively bind synthetic non-
agonist ligands [3,31^34]. There are several examples of
receptor^recombinase fusions that have been modi¢ed to
selectively mediate recombination in response to known
receptor antagonists [35^39]. However, relatively few ex-
amples of transcriptionally active ligand^receptor com-
plexes have been reported and in many cases their selec-
tivity is limited [33,34,40^42]. The high-resolution crystal
structures of the LBDs of several members of the nuclear/
steroid hormone receptor family have been solved [43^51]
and provide the basis for the rational molecular design of
receptors as they can be selectively activated by synthetic
hormone analogs [31,52,53].
2.2. Manipulation of polar groups may provide greater
ligand^receptor selectivity
Manipulation of key polar binding interactions, hydro-
gen bonds or salt-bridges, between ligand and receptor
may help create receptors that can better discriminate
against their natural ligand in preference for an appropri-
ate synthetic analog. In addition, it is often desirable to
add polar and/or charged functionality to ligands in order
to alter their solubility and pharmaco-kinetic properties.
Salt-bridges and other polar interactions within a pro-
tein’s core can enhance both the speci¢city and stability of
the protein^ligand complex as well as the folded form of
the protein. The introduction of polar groups into the
hydrophobic core of proteins is typically associated with
an unfavorable energetic cost of desolvation, which is gen-
erally o¡set by the formation of substantial hydrogen
bonding, and dipolar interactions with the protein
[54,55]. Ligand^receptor design strategies that alter
charged polar interactions are often observed to a¡ord
ligand^receptor pairs of notably lower potency [53,56].
Fig. 1. Mechanism of steroid hormone receptor action. Upon ligand binding, steroid receptors dissociate from HSPs, dimerize and bind HREs and acti-
vate transcription through interaction with transcriptional co-activators (Co). (LBD = ligand-binding domain; DBD = DNA-binding domain.)
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Previously we demonstrated that a neutral amide and a
cationic guanidine-functionalized analog of retinoic acid
could preferentially activate mutant forms of the retinoic
acid receptor to which neutral or acidic (anionic) residues
were introduced by mutagenesis [53]. These ‘charge-neu-
tralized’ and ‘charge-reversed’ ligand^receptor pairs exhib-
it relatively poor potency and selectivity and therefore did
not represent a practical tool for selective gene regulation.
The co-crystal structure of the estradiol (E2)-bound
form of human ER (hER) shows that the 3-hydroxyl of
estrogen is held via hydrogen bonds to an intra-molecular
protein salt-bridge formed by Glu353 and Arg394, which
are adjacent to the ligand-binding pocket (Fig. 2a) [47,48].
Glu353 and the 3-hydroxyl group of E2 have been shown
to be important for the selectivity and a⁄nity of E2 bind-
ing [42,57,58].
We envisioned that an orthogonal ligand^receptor pair
could be generated by substituting the intra-molecular
protein salt-bridge for an inter-molecular protein^ligand
salt-bridge created by removing the carboxylate of
Glu353 and replacing it with a carboxyl group attached
to the ligand (Fig. 2b). Ideally, this new ‘polar-group-ex-
changed’ complex should retain a network of polar inter-
actions similar to the native complex, and only di¡er in
the covalent connectivity of key polar functional groups.
2.3. Ligand^receptor pairs designed on the basis of
agonist-bound site models
We sought to test if carboxylic acid-functionalized ana-
logs of E2 could bind to an ER mutant, hER(E353A),
which has the anionic salt-bridge partner of Arg394 re-
placed by the small neutral side-chain of alanine. We de-
signed three carboxylic acid-functionalized estrogen ana-
logs to bind the modi¢ed receptor hER(E353A) by
computer-aided molecular design using Flo/Qxp (Thistle-
soft) [59].
Generally, hormone receptors undergo substantial struc-
tural reorganization upon ligand binding and undergo a
series of inter-molecular events which include dissociation
of HSPs, dimerization, DNA binding and association with
transcriptional co-activators [15^17]. Clearly, the apparent
association energies (Easss) calculated from constrained
site models based on the active E2-bound complex cannot
be expected to represent the overall energetics associated
with ligand-dependent transactivation. However, it is rea-
sonable to view a ligand’s ability to bind the active con-
formation of the receptor as a prerequisite for ligand ac-
tivity.
The compounds ES6, ES7 and ES8 were selected for
synthesis and further study on the basis of their apparent
Easss calculated for their association to constrained site
models of hER(E353A) created from the coordinates of
the reported E2^ER co-crystal structure (Fig. 3a). Monte
Carlo docking simulations performed with the ER(E353A)
site model show that the ligands ES6, ES7 and ES8 can
bind with favorable energies and with minimized struc-
tures virtually superimposable with that of the reported
structure of E2 bound in the native complex (Fig. 3b^d).
These ligands were synthesized from the 3-tri£ate of E2 by
palladium-mediated cross-couplings to create analogs with
di¡erent carboxyl tethers (Scheme 1) [60^62].
2.4. Ligand activities in cell culture
Ligand-dependent transcription assays were performed
using the modi¢ed ER HEO, which contains a
Gly400CVal mutation [65]. The modi¢ed receptor HEO
is commonly employed in place of the ‘true wild-type’
receptor (HEGO) in transiently transfected cells to mini-
Fig. 2. (a) The intra-molecular protein salt-bridge between Glu353 and Arg394 provides key hydrogen bonding partners for the phenol hydroxyl of E2.
(b) The mutation Glu353CAla causes loss of the anionic, carboxylate salt-bridge partner. Carboxylate-functionalized ligands may act in lieu of the re-
moved carboxylate to form an inter-molecular, protein^ligand salt-bridge.
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Fig. 3. Comparison of native ER^E2 complex (a) and modeled ‘polar-group exchanged’ ligand^receptor pairs ES6 (b), ES7 (c) and ES8 (d).
Scheme 1. Synthesis of carboxylate-functionalized ligands ES6, ES7 and ES8: (a) methyl acrylate, Pd(PPh3)2Cl2, LiCl, DMF, 90^100‡C/18 h [60] ;
(b) KOH, MeOH^H2O; (c) CO, AcOK, (AcO)2Pd, dppf, DMSO, 60‡C/3 h [63] ; (d) Ac2O/Pyr, THF, 0‡C; (e) allyltributyl tin, Pd(PPh3)2Cl2, LiCl,
DMF, 90‡C/4 h [61]; (f) NaIO4/RuCl3^H2O, CH3CN^CCl4^H2O, RT/1 h [64] ; (g) KOH, MeOH^H2O, re£ux/2 h.
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mize high background activity associated with the wild-
type in the absence of added ligand [66]. The three ligands,
ES6, ES7 and ES8, were evaluated for their ability to
activate reporter gene expression in human embryonic kid-
ney 293 (HEK293) cells transiently cotransfected with an
ER-responsive luciferase reporter (ERE-luc) and either the
mutant HEO(E353A) or the ‘modi¢ed wild-type’ receptor
HEO (Fig. 4). Ligands generally show similar selectivities
(but activate at lower concentrations) when the true wild-
type HEGO or HEGO(E353A) are employed, however
EC50s could not be accurately determined due to the
high background activities observed for HEGO in the ab-
sence of ligand.
The dose^response data clearly show that cells express-
ing the mutant receptor HEO(E353A) show almost wild-
type transactivation activity towards nanomolar concen-
trations of the ligand ES8 (EC50 = 60 nM). Only a very
weak transactivation response is observed with
HEO(E353A) at concentrations of E2 at or below 1000
nM, which is substantially higher than in vivo levels of
E2 which are typically below 1.3 nM (Fig. 4A) [67]. The
ligands ES6 and ES7 also show little to no activity at
concentrations up to 1000 nM suggesting that the precise
length and conformational preferences of the carboxyl
tether are critical for activity towards the mutant receptor.
Importantly, ES8 is unable to elicit a signi¢cant transacti-
vation response in cells expressing the modi¢ed wild-type
HEO at concentrations below 1000 nM whereas E2 is
active at low nanomolar concentrations (EC50 = 4.1 nM)
(Fig. 4B). ES8 also shows no activity towards cells trans-
fected with reporter only. Together the data demonstrate
that polar-group exchange can be an e¡ective strategy for
generating functionally orthogonal ligand^receptor pairs
where the ligand can selectively activate the modi¢ed re-
ceptor at concentrations that do not activate the native
receptor and the modi¢ed receptor is not activated by
endogenous concentrations of natural ligand.
2.5. Activity results are supported by in vitro ligand binding
The observation that cells expressing HEO(E353A)
show a strong transactivation response towards ES8 and
not towards the structurally similar ligands ES6 and ES7,
supports the notion that the activity of ES8 is related to its
interactions with HEO(E353A) and not from non-speci¢c
interactions with the cell. The ability for the ligands E2,
ES6 and ES8 to bind the ‘true wild-type’ HEGO(wt) and
the mutant HEGO(E353A) was also assessed by radioli-
gand displacement assays using the LBD of HEGO(wt)
and that of HEGO(E353A) expressed in Escherichia coli
following standard methods (Table 1) [68,69]. In vitro
studies are consistent with the observed in vivo selectivity
of ES8. Interestingly, ES6 binds HEGO(E353A) with high
a⁄nity (Kd = 10.8 nM) as was predicted by modeling stud-
Fig. 4. Dose^response behavior of (A) HEO(E353A) and (B) ‘modi¢ed wild-type’ receptor HEO towards E2 (F), ES6 (R), ES7 (S), and ES8 (7).
Data are mean þ S.E.M. of six independent experiments run in triplicate.
Table 1
Comparison of in vitro ligand-binding constants (Kd), observed activities in cell culture (EC50) and calculated apparent Eass
Entry Receptor Ligand Eass (kJ/mol) EC50 (nM)a Kd (nM)b
1 hER(wt) E2 342.8 3.6 þ 0.4 0.15 þ 0.5
2 hER(wt) ES6 340.8 s 1000 68 þ 20
3 hER(wt) ES7 331.4 s 1000 n.d.
4 hER(wt) ES8 320.7 s 1000 107 þ 30
5 hER(E353A) E2 331.4 s 1000 60 þ 20
6 hER(E353A) ES6 352.2 s 1000 10.8 þ 1.0
7 hER(E353A) ES7 344.0 s 1000 n.d.
8 hER(E353A) ES8 353.7 60 þ 15 7.2 þ 0.5
aEC50s determined using HEO with values reported as þ S.E.M. of six independent experiments performed in triplicate.
bKds determined using HEGO reported as þ S.E.M. of four experiments performed in triplicate.
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ies, but evidently does not show activity in HEO(E353A)
in the concentration range of our assay.
Although the apparent Easss calculated in the absence of
explicit solvent cannot be expected to accurately compare
structurally dissimilar ligands towards a speci¢c receptor,
it is noteworthy that the calculations predict the relative
selectivities of E2, ES6 and ES8 towards ER(wt) and
ER(E353A). In addition, modeling accurately predicted
the relative a⁄nities of the carboxylate-functionalized li-
gands ES6 and ES7 towards the mutant ER(E353A) and
towards the native ER(wt). Taken together this suggests
that site models of ligand-bound complexes provide a use-
ful guide for rational molecular design of new receptor
agonists.
3. Signi¢cance
This work describes a new rational design strategy
called ‘polar-group exchange’ for engineering orthogonal
ligand^receptor pairs. This strategy which involves altering
the covalent connectivity of polar/charged groups adjacent
to a ligand-binding pocket is used to create a mutant from
the ER that selectively activates gene expression upon
binding a rationally designed synthetic estrogen analog
which does not activate the endogenous ER. The modi¢-
cation of receptor side-chains that are involved in ligand^
receptor hydrogen bonds of the native complex provides a
mechanism to actively discriminate against binding the
natural ligand.
In this study we show that the mutant ER(E353A) has a
400-fold lower a⁄nity for E2 and should not be responsive
to endogenous concentrations of E2. However, ES8 can
provoke a strong transcriptional response in cells express-
ing ER(E353A) at concentrations that do not activate cells
expressing ER(wt). Apparent Easss calculated from site
models based on the agonist-bound crystal structure are
consistent with the results of in vitro ligand binding and
cellular transactivation assays suggesting that molecular
modeling of agonist-bound structures provides a useful
guide to ligand^receptor design within the steroid hor-
mone receptor family. With further re¢nement, this func-
tionally orthogonal ligand^receptor pair should constitute
a new tool for remote regulation of eukaryotic gene ex-
pression.
4. Materials and methods
4.1. General
All compounds were purchased from Aldrich unless otherwise
noted. Tetrahydrofuran (THF) and ether were distilled from so-
dium benzophenone ketyl under nitrogen. Unless noted other-
wise, all reactions were performed under a nitrogen atmosphere.
Nuclear magnetic resonance (NMR) spectra were recorded on a
Bruker DRX-400 spectrometer at the University of Delaware
NMR facility. All chemical shifts are reported as N (ppm) refer-
enced to tetramethylsilane (TMS). Mass spectroscopy was per-
formed at the University of Illinois mass spectrometry laboratory
and the University of Delaware mass spectrometry laboratory.
Oligonucleotides were purchased from The Great American
Gene Company, Ransom Hill Bioscience Inc. Chromatography
was performed using ICN SiliTech (60) £ash silica. HEK293 cells
(American Type Tissue Culture Collection) were maintained at
the University of Delaware Cell Culture Core Facility. Transac-
tivation response assays were performed using the Dual-Lucifer-
ase Reporter Assay System (Promega #E1960) following the
manufacturer’s protocol. Radiolabeled E2 ([3H]E2) ([2,4,6,7-
3H]estra-1,3,5,(10)-triene-3,17-diol), 84.0 Ci/mmol, was obtained
from Amersham Pharmacia Biotech UK (Arlington Heights, IL,
USA). Unlabeled E2, butylated hydroxyanisole (BHA), isopro-
pyl-D-thiogalactopyranoside (IPTG), leupeptin, aprotinin, pepsta-
tin and phenylmethylsulfonyl £uoride (PMSF) were obtained
from Sigma; hydroxyapatite (HAP; Bio-Rad) was prepared fol-
lowing the procedure of Williams and Gorski [69]. The pET15b
vector and BL21(DE3)pLysS cells were obtained from Novagen
(Madison, WI, USA). Cell culture media was purchased from
Mediatech (Herndon, VA, USA). Fetal bovine serum (FBS)
was obtained from Summit Biotechnology (lot # FA0727).
4.2. Molecular modeling
Molecular modeling was performed on a silicon graphics Oc-
tane using Flo98/QXP modeling software (available from This-
tlesoft, P.O. Box 227, Colebrook, CT 06021, USA; cmcma@ix.
netcom.com) [59]. Site models representing all residues within 12
Aî of bound E2, were constructed from published X-ray coordi-
nates of Brzozowski et al. [47]. (Note: the HEO mutation G400V
is remote to the ligand-binding site and is not included in the 12
Aî model.) The side-chains of all residues that contacted the li-
gand were ‘free’ during all simulations. A site model for the mu-
tant receptor ER(E353A) was generated by manually changing
the side-chain of Glu353 and performing 10 rounds of 3 ps sim-
ulated annealing with E2 bound. Ligands were evaluated using
the Monte Carlo docking (mcdock) algorithm of QXP (1000
steps) which minimizes the energy of the ligand-bound complex
starting from random conformations and orientations of the li-
gand. Apparent Easss are determined as the di¡erence between the
energy of the minimized ligand-bound complex and the sum of
the energies of the global minimum of the free ligand plus the
local minimum of the receptor. All calculations are performed in
the absence of explicit solvent using a distance-dependent dielec-
tric (4.0r, Aî ).
4.3. Plasmid constructs
Mammalian expression vectors pSG1-HEO(E353A), pSG1-
HEGO(E353A) (HEGO = ERK(wt), HEO = ERK(G400V)) were
constructed from the parent plasmids pSG1-HEO and pSG1-
HEGO [65], by oligonucleotide-directed mutagenesis using
Quickchange (Stratagene) using the following oligonucleotides:
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E353Af, CCAACCTGGCAGACAGGGCGCTGGTTCACATG-
ATCAACTGG; E353Ar, CCAGTTGATCATGTGAACCAG-
CGCCCTGTCTGCCAGGTTGG.
Prokaryotic expression vectors pET15b-ER and pET15-
b(E353A) were generated by sub-cloning of the wild-type and
mutant hormone-binding domain sequences into the NdeI and
BamHI sites of pET15b (Novagen, Madison, WI, USA) using
cloning primers 5P-GGGAATTCCATATGAACAGCCTGGC-
CTTGTCC-3P and 5P-CGCCGGATCCGCGCTAGTGGGCG-
CATGTAG-3P. All constructs were sequenced over the entire
coding region of ER to con¢rm the presence of only the desired
mutation.
4.4. Cell culture and transfections
All cell culture experiments were performed using phenol red-
free Dulbecco’s modi¢ed Eagle’s medium (DMEM). Twenty-four
h prior to transfection, HEK293 cells were seeded at a density of
40 000 cells per well in 24-well culture plates. Three h prior to
transfection, the media was changed to media made with 10%
charcoal-resin-stripped FBS [70]. Transfections were performed
by the CaPO4 method using 0.03 Wg DR43luc+, 0.14 Wg pRLba-
sic and 0.08 Wg pSG1-HEO or pSG1-HEO(E353A) per well. Six
hours after transfection, the media was removed and replaced
with DMEM+10% charcoal-resin-stripped FBS containing ap-
propriate concentrations of ligand. The cells were allowed to in-
cubate with ligand for 36 h before harvesting by passive lysis. Cell
extracts were immediately assayed using the Dual-Luciferase As-
say (Promega) using a Dynex luminometer. Activity is reported in
relative light units (RLU) determined as the ratio of the ¢re£y
luminescence divided by the luminescence of the renilla luciferase
control. Dose^response data were analyzed using non-linear re-
gression analysis of Graphpad Prism (Graphpad Software).
4.5. In vitro ligand-binding assays
The LBDs (amino acids 304^554) of ER (HEGO or HE-
GO(E353A)) were expressed in E. coli according to the procedure
of Katzenellenbogen [68]. Brie£y, 1 l of 2XYT media was inocu-
lated with overnight cultures (5 ml) of E. coli BL21(DE3)pLysS
cells expressing either pET15bHEGO-LBD or pET15bHE-
GO(E353A)-LBD. The cultures were grown at 37‡C to an
OD600 nm of 0.6^0.7. The cells were induced with IPTG and in-
cubated at 30‡C for 3 h. The cells were harvested by centrifuga-
tion (15 min at 6000Ug, 4‡C) and the cell paste resuspended in 10
ml cold lysis bu¡er (50 mM Tris (pH 7.5), 10% (v/v) glycerol, 0.1
mM BHA, 10 mM mercaptoethanol, 50 Wg/ml pepstatin A and
0.2 mM PMSF). The suspension was sonicated (Branson sonica-
tor with microprobe) for 3U10 s at 60% power. The cell debris
and the pellet fraction were separated from the supernatant by
centrifugation (10 000Ug, 20 min, 4‡C). The crude supernatant
could be used directly or diluted to the desired concentration in
binding bu¡er (50 mM Tris, pH 7.5, 10% glycerol, 0.1 mM BHA,
10 mM mercaptoethanol, 0.5% yeast extract). SDS^PAGE
analysis con¢rms the induction of an approximate 35 kDa pro-
tein for both wild-type and mutant proteins as reported [68].
Preparations of HEO(E353A)-LBD bound E2 too weakly (or
perhaps was too unstable) to determine dissociation constants
for E2 or for the compounds ES6, ES7, and ES8 by competitive
titration, therefore binding assays were performed on the true
wild-type HEGO.
The ligand-binding assays were performed according to the
procedure of Katzenellenbogen [68]. The ER was diluted to
V1.5^2 nM (or 5^10 nM for HEGO(E353A)-LBD) in binding
bu¡er and incubated with various concentrations of [3H]E2 in the
absence or presence of a 200-fold excess of unlabeled ligand for
16^18 h at 4‡C. The bound ligand was assayed by adsorption
onto HAP for 30 min at 4‡C, followed by three washes with
0.8 ml of cold 0.05 M Tris (pH 7.3). The HAP pellet was resus-
pended in 1 ml of EtOH and counted in 10 ml of scintillation
£uid. The amount of speci¢c ligand binding at each ligand con-
centration, determined as the di¡erence between the total binding
and the non-speci¢c binding, was ¢t to the following equation by
non-linear regression analysis using GraphPad InPlot (Graphpad
software):
CPM  CPMi  CPMf3CPMi
U
L0  P0  Kd3

L0  P0  Kd234P0
p
L0
2P0
where L0 and P0 are the total concentration of ligand and active
ER, respectively; CPMi and CPMf are the amount of counted
scintillation £uid at initial and saturated concentrations, respec-
tively, and Kd is the dissociate constant of ligand and receptor.
The dissociation constants for the designed ligands ES6 and
ES8 were determined by competitive titration. The tritiated trac-
er, [3H]E2 (84.0 Ci/mmol), was used at 5 nM to give the assay
greater sensitivity to measure the high a⁄nity of the E2 to wild-
type ER, while 20 nM was used for mutant due to the low a⁄nity
of E2 to mutant. The crude receptor was incubated with di¡erent
concentrations of unlabeled ligand along with 5 nM [3H]E2 (84.0
Ci/mmol) for HEGO-LBD or 20 nM [3H]E2 for HEGO(E53A)-
LBD, at 4‡C for 16^18 h. The unlabeled competitors were added
from stock solutions in dimethyl sulfoxide (DMSO) such that the
¢nal concentration of DMSO in the assay solution was 1%. Dis-
sociation constants were determined by non-linear regression
analysis using GraphPad Prism.
4.6. Analysis of ligand purity
Because of the potential for small amounts of E2 or estrogenic
impurities to cause otherwise inactive compounds to exhibit ac-
tivity, the purity of all ligands tested was rigorously established
by high-performance liquid chromatography (HPLC). All sam-
ples used were demonstrated to be homogeneous and free of
any detectable traces of E2 (to less than 0.01%) by HPLC under
conditions where the two species were well resolved.
4.6.1. 3-Carboxyl-17L-hydroxy-estra-1,3,5(10)-triene (ES6)
A mixture of 1 (3-tri£uoromethanesulfonyl-17L-hydroxy-estra-
1,3,5(10)-triene) [71] (100 mg, 0.2 mmol), potassium acetate
(0.392, 4 mmol), palladium(II) diacetate (20 mg, 0.05 mmol),
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1,1-bis(diphenylphosphino)ferrocene (dppf) (100 mg, 0.2 mmol)
in DMSO (3 ml) was purged with carbon monoxide for 5 min
and stirred under a CO balloon at 60‡C for 3 h. The reaction
mixture was diluted with 10 ml water, acidi¢ed with 5 ml 1 N
HCl and extracted with 3U15 ml CH2Cl2. The organic layer was
washed with 2U10 ml water, 10 ml brine, dried with MgSO4. The
solvent was concentrated under reduced pressure to a¡ord ES6 as
a white powder which was recrystallized from MeOH to a¡ord
55 mg of ES6 (0.18 mmol, 70.5%); mp s 260‡C; NH (400 MHz,
CD3OD) 0.72 (s, 3H), 1.18^1.59 (m, 7H), 1.71 (m, 1H), 1.89^2.34
(m, 5H), 2.84 (q, J = 4.2 Hz, 2H), 3.61 (t, J = 8.6 Hz, 1H), 7.32 (d,
J = 8.2 Hz, 1H), 7.65 (s, 1H), 7.68 (d, J = 8.2 Hz, 1H); NC (100
MHz, CD3OD) 11.77, 24.17, 27.33, 28.33, 30.79, 38.09, 39.99,
44.43, 46.18, 49.99, 51.53, 82.53, 126.68, 128.15, 129.17, 131.48,
138.26, 147.31, 170.39; HRMS (EI) calcd for C19H24O3 :
300.1725. Found: 300.1717.
4.6.2. 3-Methyl acrylic-17L-hydroxy-estra-1,3,5(10)-triene (2)
A solution of 240 mg (0.6 mmol) 1, 114 mg (1.3 mmol) methyl
acrylate, 112 mg (2.6 mmol) lithium chloride, a few crystals of
2,6-di-tert-butyl-methylphenol, and 1.0 ml triethylamine in 5 ml
DMF was sparged with nitrogen for 10 min before 40 mg (0.2
mmol) bis(triphenylphosphine)palladium dichloride was added.
The rapidly stirred suspension was then heated to 90‡C for 24
h. The mixture was allowed to cool before 20 ml 10% HCl was
added and the mixture was extracted with 3U30 ml ethyl acetate.
The organic layer was washed with brine (2U20 ml), dried over
MgSO4, and concentrated under reduced pressure. The residue
was puri¢ed by silica £ash chromatography to give 170 mg of 2
(0.5 mmol, 83.8%); mp 153^155‡C; NH (400 MHz, CDCl3) 0.77
(s, 3H), 1.24^1.52 (m, 7H), 1.75 (m, 1H), 1.96^2.37 (m, 5H), 2.5
(brs, 1H), 2.84 (q, J = 3.5 Hz, 2H), 3.71 (t, J = 8.6 Hz, 1H), 3.78
(s, 3H), 6.40 (d, J = 16 Hz, 1H), 7.21 (s, 1H), 7.28 (d, J = 7.8, 1H),
7.65 (d, J = 16 Hz, 1H); NC (100 MHz, CDCl3): 12.68, 23.55,
26.45, 27.45, 29.83, 30.78, 37.12, 38.82, 43.63, 44.99, 50.53,
52.12, 84.26, 117.06, 125.75, 126.37, 129.43, 132.04, 137.72,
143.72, 146.81, 168.15; HRMS (EI) calcd for C22H28O3 :
340.1962. Found: 340.2006.
4.6.3. 3-Acrylic acid-17L-hydroxy-estra-1,3,5(10)-triene (ES8)
To a solution of 50 mg (0.15 mmol) of 2 in 5 ml ethanol was
added 2 ml of 1 M NaOH and the solution was heated to re£ux
for 1 h. After cooling to ambient temperature, the solution was
acidi¢ed by addition of 1 M HCl and extracted with 2U10 ml
EtOAc. The combined organic extracts were dried over MgSO4
and concentrated under reduced pressure to a¡ord a light yellow
powder. The crude product could be further puri¢ed by recrys-
tallization twice from MeOH to a¡ord 35 mg (0.11 mmol, 73%)
of pale yellow prisms: mp 238^240‡C; NH (400 MHz, CD3OD)
0.75 (s, 3H), 1.25^1.50 (m, 7H), 1.71 (m, 1H), 1.80^2.34 (m, 5H),
2.84 (q, J = 4.3 Hz, 2H), 3.63 (t, J = 8.6 Hz, 1H), 6.37 (d, J = 16
Hz, 1H), 7.24 (s, 1H), 7.30 (d, J = 8.6 Hz, 2H), 7.58 (d, J = 16 Hz,
1H); NC (100 MHz, CD3OD) 11.28, 24.17, 27.38, 28.38, 30.81,
38.11, 40.14, 44.45, 45.02, 46.09, 51.25, 82.55, 118.23, 126.56,
127.18, 130.07, 133.16, 138.69, 143.82, 146.78, 170.80; HRMS
(EI) calcd for C21H26O3 : 326.1882. Found: 326.1871.
4.6.4. 3-Tri£uoromethanesulfonyloxy-17L-acetoxy-estra-
1,3,5(10)-triene (3)
To a solution of tri£ate 1 (1.06 g, 2.5 mmol) in pyridine (3 ml)
at 0‡C was added acetic anhydride (1.0 ml, 10 mmol). The reac-
tion was allowed to stir at ambient temperature for 24 h before
water (100 ml) was added and the resulting mixture partitioned
with ether (50 ml). The organic extract was washed with 20 ml 1 N
HCl, 3U20 ml CuSO4, 2U20 ml water, 20 ml brine and was
dried over MgSO4. The organic layer was evaporated under re-
duced pressure, and the residue was recrystallized from EtOH to
a¡ord 1.02 g (2.3 mmol, 90%) of ¢ne, white needles: mp 56^
58‡C; NH (400 MHz, CDCl3) 0.83 (s, 3H), 1.38^1.49 (m, 7H),
1.75 (m, 1H), 1.91 (m, 2H), 2.06 (s, 3H), 2.25 (m, 3H), 2.89
(dd, J = 8.8, 4.2 Hz, 2H), 4.69 (dd, 8.0, 7.8 Hz, 1H), 6.96, (d,
J = 2.6 Hz, 1H), 7.01 (dd, J = 8.6, 1.6 Hz, 1H), 7.33 (d, J = 8.7
Hz, 1H); NC NMR (100 MHz, CDCl3) 12.19, 21.37, 23.40, 26.13,
26.93, 27.69, 29.66, 36.93, 38.11, 42.98, 44.09, 49.95, 82.36,
117.31, 118.31, 121.32, 127.38, 139.69, 140.91, 147.64, 171.39;
HRMS calcd for C21H25F3SO5 : 446.1375. Found: 446.1397.
4.6.5. 3-Allyl-17L-acetoxy-estra-1,3,5(10)-triene (4)
A solution of 220 mg (0.5 mmol) of 3, 0.17 ml (0.55 mmol)
allyltributyl tin, 68 mg (1.6 mmol) lithium chloride and 1 mg 2,6-
di-tert-butyl-4-methylphenol in 3 ml DMF was sparged with ni-
trogen for 10 min before 10 mg (0.05 mmol) bis(triphenylphos-
phine)palladium dichloride was added. The resulting suspension
was then heated to 90‡C for 4 h. The reaction mixture was al-
lowed to cool to room temperature, and treated with 0.2 ml
pyridine and 0.4 ml HF^pyridine. This mixture was allowed to
stir at room temperature overnight. The mixture was then diluted
with ethyl ether, ¢ltered through a small pad of Celite, and
washed with 10 ml water, 10 ml 10% HCl, 10 ml water and 10
ml brine. The organic layer was dried over MgSO4, and concen-
trated under reduced pressure. The residue was puri¢ed by silica
£ash chromatography to give 130 mg (0.42 mmol, 84% yield) of
4 : mp 101^102‡C; NH (400 MHz, CDCl3) 0.82 (s, 3H), 1.21^1.59
(m, 7H), 1.71 (m, 1H), 1.89 (m, 2H), 2.06 (s, 3H), 2.15^2.34 (m,
5H), 2.85 (m, 2H), 3.33 (d, J = 6.8 Hz, 2H) 4.68 (t, J = 8.1 Hz,
1H), 5.06 (m, 1H), 5.95 (m, 1H), 6.92 (s, 1H), 6.98 (d, J = 8.6 Hz,
1H), 7.23 (d, J = 8.6 Hz, 1H); NC (100 MHz, CDCl3) 12.22, 21.39,
23.42, 26.13, 27.32, 28.02, 29.62, 37.05, 37.92, 38.48, 43.04, 44.28,
50.02, 82.88, 94.32, 103.89, 125.80, 126.99, 130.31, 131.86, 137.05,
139.20, 171.44.
4.6.6. 3-Carboxymethylene-17L-acetoxy-estra-1,3,5(10)-triene (5)
To a rapidly stirred solution of 70 mg (0.2 mmol) of 3 in 0.5 ml
carbon tetrachloride and 0.5 ml acetonitrile was added a solution
of 142 mg (0.68 mmol) sodium metaperiodate in 0.75 ml water
and 1 mg (0.01 mmol) ruthenium trichloride hydrate. The result-
ing suspension was stirred at ambient temperature for 1 h and
then diluted with 50 ml of methylene dichloride. The layers were
separated, and the organic phase washed with 10 ml water, 10 ml
brine, dried over MgSO4 and concentrated under reduced pres-
sure. The residue was puri¢ed by silica gel £ash chromatography
to give 35 mg (0.1 mmol, 50% yield) of 5 : NH (400 MHz, CDCl3)
0.77 (s, 3H), 1.24^1.50 (m, 7H), 1.71 (m, 1H), 1.92 (m, 2H), 2.06
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(s, 3H), 2.15^2.34 (m, 5H), 2.84 (m, 2H), 3.57 (s, 2H), 4.68 (t,
J = 8.1 Hz, 1H), 7.00 (d, J = 8.6 Hz, 1H), 7.14 (s, 1H), 7.26 (d,
J = 8.6 Hz, 1H); NC (100 MHz, CDCl3) 14.41, 21.35, 23.46, 25.06,
26.14, 27.26, 28.06, 29.61, 37.02, 43.06, 45.56, 50.01, 67.81, 82.80,
125.82, 127.56, 130.98, 137.25, 139.77, 146.84, 171.54, 171.71.
4.6.7. 3-Carboxymethylene-17L-hydroxy-estra-1,3,5(10)-triene
(ES7)
To a solution of 20 mg (0.06 mmol) of 5 in 5 ml ethanol was
added 2 ml of 1 M NaOH and the solution heated to re£ux for
1 h. The solution was allowed to cool to ambient temperature
and acidi¢ed with 1 M HCl, which resulted in the formation of a
white precipitate. The mixture was extracted with 2U10 ml
EtOAc, and dried over MgSO4. The solution was concentrated
under reduced pressure to a¡ord a light yellow powder. An an-
alytical sample was obtained by recrystallization twice from
MeOH to give 12 mg (0.04 mmol, 68%) of a white solid: NH
(400 MHz, CD3OD) 0.78 (s, 3H), 1.25^1.50 (m, 7H), 1.70 (m,
1H), 1.94 (m, 2H), 2.11^2.34 (m, 5H), 2.84 (m, 2H), 3.51 (s, 2H),
3.74 (t, J = 8.1 Hz, 1H), 6.97 (d, J = 8.6 Hz, 1H), 7.14 (s, 1H), 7.26
(d, J = 8.6 Hz, 1H); NC (100 MHz, CD3OD) 11.77, 24.17, 27.34,
28.33, 30.08, 30.56, 30.81, 38.10, 40.01, 44.43, 46.19, 51.55, 82.60,
126.67, 128.14, 129.12, 131.47, 138.27, 147.34, 170.36; HRMS
(EI) calcd for C20H26O3 : 314.1882. Found: 314.1876.
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